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ABSTRACT:  
We systematically reviewed published pharmacological treatment data for ''mixed states/episodes'' 
in mood disorders including ''with mixed features'' in DSM-5. We searched: PUBMED, MEDLINE, 
COCHRANE LIBRARY, clinicaltrials.gov, current-trials.com (key words: "mixed states/features" 
AND "bipolar" AND "depressive symptoms/bipolar depression" AND "manic symptoms" AND 
"treatment" AND "DSM-5”) to April 2016. We applied a quality of evidence approach (first-degree 
evidence: randomised placebo controlled studies of pharmacological interventions used in 
monotherapy; second-degree evidence comprised a similar design in the absence of a placebo group 
or of combination therapy; third degree evidence comprised case reports, case series, post-hoc 
analysis of primary data, non-controlled cohort studies and reviews of published studies). 
We found very little primary double-blind, placebo-controlled studies of the treatment of mixed 
states:  the preponderance of available data derives from sub-group analysis performed on studies 
that originally involved manic patients.  
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Introduction 
 
Mixed states present particular challenges to the treating clinician and even the prevalence rate 
changes significantly among studies and in relation to diagnostic criteria used.  In DSM-IV, a 
diagnosis of a mixed episode required simultaneously all criteria for a manic or a major depressive 
episode. In clinical practice individuals infrequently meet these full criteria.  After a 14-year 
development process including approximately 400 people from different professions and 39 
countries, DSM-5 appeared in May 2013. The new DSM-5 ''specifier'' adopts a broader approach 
towards mixed states.  In the case of depressive episodes, there is a requirement for the presence of 
at least three manic/hypomanic symptoms (including elevated mood, inflated self-esteem, decreased 
need for sleep and an increase in energy or goal-directed activities), occurring nearly every day 
during the most recent two weeks of the major depressive episode, notably overlap with symptoms 
of major depression is restricted. In the case of mania or hypomania, the specifier requires the 
presence of at least three symptoms of depression (including depressed mood, diminished interest 
or pleasure, slowed physical and emotional reaction, fatigue or loss of energy, and recurrent 
thoughts of death) together with the episode of mania/hypomania, nearly every day throughout the 
most recent week of a manic episode or during the most recent four days of a hypomanic episode.  
 
Mixed states are generally held to be less responsive to pharmacological treatment and response to 
mood stabilizers and other pharmacotherapies is poor1,2. Antidepressants are generally avoided 
because of exacerbation of manic symptoms and a feared increased risk of suicidality which is 
already high3.  However, the use of an atypical antipsychotic-antimanic agent in some bipolar 
disorder patients may decrease suicidal ideation4. As a result, the choice of medication is usually 
based on individual factors and short/long-term harms, safety and tolerability parameters. The aim 
of this review is to review the pharmacological treatment of ''mixed states/episodes'' as defined by 
DSM-IV and DSM-5 manic episodes ''with mixed features'' . 
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Methods 
Searches 
PUBMED, MEDLINE, and the Cochrane library were searched from January 1980 to April 2016 
for all publications regarding treatment of mixed features as defined by DSM-IV and DSM-5 manic 
episodes ''with mixed features''.  Clinical trials registries, ‘clinicaltrials.gov’ and ‘controlled-
trials.com’, were scrutinised for trials.  Search terms included: “Mixed states OR Mixed features” 
AND “Bipolar disorder’’ AND “depressive symptoms OR bipolar depression” AND “Manic 
symptoms’’ AND “Treatment’’ AND ‘’DSM-5’’.  Related publications were hand searched from 
the reference lists of every identified primary study.  
Study selection 
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)5 
guidelines.  Articles were screened and selected for full-text review if they met our selection 
criteria. Once identified titles and abstracts were reviewed independently by two the authors (AC,, 
AY) and discrepancies were resolved by consensus among all the authors. 
Quality assessment 
First-degree studies included double blind, placebo controlled randomised controlled trials (RCTs) 
of pharmacological interventions used in monotherapy. Second-degree referred to a similar design 
without placebo group +/- combination therapy and third degree referred to any other type of 
published studies.  
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Results 
The searches identified 913 studies of which 73 met inclusion criteria and investigated mixed states 
in bipolar disorder. Non-original studies (including editorials, book reviews and letters to the editor) 
and studies without full-text available were excluded.  
These studies evaluated antipsychotics (n=39), mood stabilizers (n=14) and combination therapies 
(n=20) in patients with DSM-IV mixed episodes or DSM-5 mixed features. Pharmacological 
evidence for each class of medication is described below and organised according to clinical 
presentation, length of treatment and degree of evidence (Supplementary Tables with details 
available upon request).  
Antipsychotic medication with mood stabilising properties 
1) OLANZAPINE 
Acute treatment studies (≤ 8 weeks) 
We identified two first degree studies comparing olanzapine with placebo 6,7, one second degree 
evidence study comparing olanzapine with haloperidol8 and two with risperidone9,10. 
Longer term (≥ 8 weeks), maintenance and relapse prevention studies 
We identified six second degree studies. One open label post-hoc analysis compared olanzapine 
with placebo and further five trials compared olanzapine with haloperidol (6-week continuation 
phase), sodium valproate, lithium and asenapine in two reports (see below for asenapine). A post 
hoc-analysis open label study of a randomized, placebo-controlled trial11 compared olanzapine with 
placebo in mixed episode patients for 6-12-week 12.  A subsequent 6-week continuation phase of 
Tohen et al. 12-week comparison trial was also identified (olanzapine vs haloperidol)10.  Tohen and 
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others13 analyzed the efficacy of olanzapine vs. valproate in the treatment of mania and mixed 
episodes.  A further study of 52 weeks14 compared the efficacy of olanzapine and lithium 
monotherapy in relapse/recurrence prevention of mood episodes among remitted patients previously 
treated with a combination therapy of these two compounds (for 6-12 weeks).  
2) QUETIAPINE 
Acute treatment  (≤ 8 weeks) 
We identified five first degree acute phase studies. Three studies compared quetiapine with placebo 
15-17 and two compared quetiapine with lithium or paroxetine and placebo18,19. Another randomized 
controlled study compared quetiapine with paliperidone extended release to placebo (see 
paliperidone). A second degree evidence continuation phase of the study which compared 
quetiapine with paliperidone without placebo is descibed below (see paliperidone)20. 
Longer term (≥ 8 weeks), maintenance and relapse prevention studies  
One maintenance study compared quetiapine with lithium and placebo as open label extension of a 
randomised controlled trial in Bipolar I disorder for up to 104 weeks 21..  
3) ARIPIPRAZOLE  
Acute treatment (≤ 8 weeks) 
We identified five first degree evidence acute phase trials with aripiprazole. Four studies compared  
aripiprazole with placebo 22-25 and one with lithium and placebo 26. A one second degree    
evidence comparison trial analyzed the efficacy of aripiprazole vs. haloperidol27. 
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Longer term (≥ 8 weeks), maintenance and relapse prevention studies  
We identified one first degree long term trial which compared aripiprazole with placebo 28 and two 
second degree extension studies26,27 comparing aripiprazole with lithium and haloperidol 
respectively (the treatment received in the first 3 week of treatment are discussed above).  
4) ASENAPINE 
Acute treatment (≤ 8 weeks) 
There are two first degree evidence trials29,30 assessing asenapine in the managment of mixed 
affective symptoms compared with olanzapine and placebo. McIntyre and others combined the 
above described studies29,30 in a post-hoc analysis31 based on the DSM-5 mixed specifier for the 
diagnosis of manic episodes. 
Longer term (≥ 8 weeks), maintenance and relapse prevention studies  
We reported two second degree evidence trials regarding long term treatment of asenapine 
compared with olanzapine by McIntyre and others. The authors designed these two stepped 
progressive studies originating from the first 3 week trial by randomising the placebo group into 
active treatment32,33. 
5) LURASIDONE 
Acute treatment (≤ 8 weeks) 
We found evidence of efficacy in acute bipolar depression, supported by two monotherapy 
randomized clinical trials34,35 and one second degree adjunctive therapy study (see combination 
therapy)36.  
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Longer term (≥ 8 weeks), maintenance and relapse prevention studies  
No studies were identified. 
6) ZIPRASIDONE 
Acute treatment (≤ 8-weeks) 
We identified one first degree evidence trial assessing efficacy of ziprasidone compared with 
placebo in major depressive episodes with 2 or 3 concomitant manic symptoms37. A second degree 
study is available from a pooled analysis38 of mixed patient with dysphoric mania previously 
enrolled in two similar placebo controlled trials39,40.  
 
Longer term (≥ 8 weeks), maintenance and relapse prevention studies  
No studies were identified. 
7) RISPERIDONE 
Acute treatment  (≤ 8-weeks) 
We identifyed one firts degree trial41 comparing risperidone to placebo in mixed affective 
conditions. 
Longer term (≥ 8 weeks), maintenance and relapse prevention studies  
No studies were available. 
8) PALIPERIDONE 
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Acute treatment (≤8-weeks) 
We indentified two first degree trials20,42 assessing efficacy of paliperidone in mixed affective 
conditions.  
Longer term (≥ 8 weeks), maintenance and relapse prevention studies  
Vieta et al. performed a randomized, placebo- active-controlled study of paliperidone extended 
release for the treatment of acute manic and mixed Bipolar I disorder 20..  
9) CLOZAPINE 
Acute and maintenance treatment  
In a case series by Suppes and others 85 consecutive patients were treated with clozapine. Seven 
subjects had treatment-resistant bipolar disorder and manic episodes associated with significant 
depressive symptoms. All patients displayed significant reductions in affective and psychotic 
symptoms when treated with clozapine alone or in combination with lithium, an antidepressant, or 
sodium valproate. Clozapine effects were often evident within the first few weeks of treatment and 
sustained over the 3-5 years follow-up period43. 
10) CARIPRAZINE 
Acute treatment (≤ 8-weeks) 
The three identified first degree randomized controlled trials measured the effect of cariprazine on 
manic and depressive symptoms in acute mania or mixed episodes 44-46.  
 
Longer term (≥ 8 weeks), maintenance and relapse prevention studies  
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Longer-term treatment of subjects with Bipolar I illness was investigated in an open, 16-week study 
that followed up 402 patients47,48.  
 
Ongoing trials 
An ongoing international 8-week study49 of cariprazine vs. placebo in bipolar depression registrated 
on the ClinicalTrials.gov website is currently investigating subjects with Bipolar I depression with a 
verified previous manic or mixed episode, without psychotic features, aged 18–65 , total HAMD 
score of ≥20, HAMD Item 1 score of ≥2, and CGI-S of ≥4 to be randomized to cariprazine 0.75, 
1.5, or 3.0 mg/day, or placebo.  
 
Mood stabilizers in managment of mixed affective features 
 
1) DIVALPROEX 
 
Acute treatment (≤ 8 weeks) 
We found four first degree Divalproex vs. placebo acute treatment trials50-53.  
 
Maintenance treatment (≥ 8 weeks)  No maintenance or relapse prevention trials with divalproex 
monotherapy were found. Comparison studies are analized in the section below (see lithium). 
2) LITHIUM  
Acute treatment (≤ 16 weeks) 
We identifyed two second degree comparison trials with divalproex (in manic/mixed bipolar 
patients) 54 or lamotrigine55 in bipolar depression. 
Maintenance/relapse prevention treatment (≥ 16 weeks) 
Only one trial was identified comparing lithium monotherapy vs. placebo as a prophylactic 
intervention in major unipolar depression and hypomania in bipolar disorder56. Three long-term 
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phase trials compared lithium with divalproex and placebo57 and two lithium with lamotrigine and 
placebo (described with lamotrigine below). 
3) CARBAMAZEPINE 
Acute treatment (≤ 8 weeks) 
Weisler and others58 reported a post hoc analysis of two randomised controlled studies59,60. The first 
trial showed higher response rates in mixed or manic patients treated with carbamazepine-extended 
release (CBZ-ER) vs. placebo (42% vs. 22% rispectively). The second trial reported response rates 
in acute manic patient treated with CBZ-ER vs. placebo in the range of 60.8% and 28.7% 
respectively for mixed patients suggesting that carbamazepine might be effective to treat both 
manic and depressive symptoms.  
Maintenance treatment (≥ 8 weeks) 
Ketter and colleagues61, in an additional secondary analysis confirmed that also long-term 
monotherapy with extended-release is efficacious against Bipolar I disorder mixed and manic 
episodes.  
4)  LAMOTRIGINE 
Acute treatment (≤ 16 week) 
We found only one first degree study of Bipolar I disorder experiencing a major depressive episode 
treated with lamotrigine (50 or 200 mg/day) or placebo in monotherapy for a 7-week period. 62   
Maintenance/ relapse prevention (≥ 16 weeks) 
Two first degree trials compared lamotrigine with lithium63,64.  
5) GABAPENTIN 
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Only one open label study investigated gabapentin as adjunctive treatment for treatment resistant 
Bipolar mixed states presenting at both poles of the illness65.  
 
COMBINATION THERAPY  
1) ARIPIPRAZOLE PLUS MOOD STABIZERS  
Acute treatment (≥ 8 weeks) 
One trial investigated aripiprazole adjuvant to other mood stabilizers (lithium or valproate) in the 
treatment of acute phase mixed states66.  
Longer term maintenance or relapse prevention (≥ 8 weeks) 
Two first degree trials67,68 compared aripiprazole adjunct to a stabilizers (lithium/valproate and 
lamotrigine) vs. placebo. A further second degree extension trial compared aripiprazole with lthium 
or valproate without the placebo arm69. 
 
2) OLANZPINE PLUS MOOD STABILIZERS 
Acute treatment (≤ 8 weeks) 
Three first degree trials compared olanazapine with a mood stabilizer (lithium or valproate) vs. 
placebo 70-72.  
Longer term maintenance/relapse prevention (≥ 8 weeks) 
Tohen et al. followed up patients who achieved syndromic remission for 18 months in a double-
blind trial 73, derived from the 6 weeks trial discussed above 71 . 
 
3) OLANZPINE – FLUOXETINE COMBINATION (OFC) 
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Acute treatment (≤ 8 weeks) 
One first degree study74 compared olanzapine monotherapy and in combination (OFC) vs. placebo 
which included a post-hoc mixed depressed patients analysis. Two second degree trials were also 
available assessing OFC vs. lamotrigine in bipolar depression with fixed 75  and flexible doses 76.  
Longer term maintenance and relapse prevention (≥ 8 weeks) 
Brown and others also conducted a 6-month long-term follow-up trial77 of the 7-week study above76 
and reported greater response of OFC flexible doses in comparison with lamotrigine (titrated up to 
200 mg/day) for both depressive and manic symptoms in Bipolar depression.  
 
4) QUETIAPINE PLUS MOOD STABILIZERS 
Acute treatment (≤ 8 weeks) 
Suppes and others assessed adjunctive quetiapine treatment in Bipolar II patients experiencing 
hypomania with mixed symptoms in a two-site, randomized, placebo-controlled, double-blind, 8-
week investigation 78.  
 
Longer term maintenance/relapse prevention  (≥ 8 weeks) 
Two placebo-controlled trials79,80 evaluated maintenance treatment with quetiapine (compared to 
placebo) as an adjunct to  lithium or divalproex. 
 
 
5) RISPERIDONE PLUS MOOD STABILIZERS 
Acute treatment (≤ 8 weeks) 
No studies were found. 
Longer term manitenzance/relapse prevention (≥ 8 weeks) 
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Woo and others investigated the efficacy of risperidone in combination with mood stabilizers in a 
24-week, open-label third-degree combination trial 81. 
  
 
6) LURASIDONE PLUS MOOD STABILIZERS  
Acute treatment (≤ 8 weeks) 
Loebel and others investigated the efficacy of lurasidone as adjunctive therapy with lithium or 
valproate for the treatment of Bipolar I depression in a 6-week, randomized, placebo-controlled trial 
36.  
Longer term maintenance/relapse prevention  
No trials available for review. 
7) ZIPRASIDONE PLUS MOOD STABILIZERS 
Acute treatment (≤ 8 weeks) 
 
No trials available for review. 
 
 
Longer term maintenance/relapse prevention (≥ 8 weeks) 
Bowden and colleagues assessed the maintenance efficacy of ziprasidone compared to placebo as 
an adjunct to a mood stabilizer in manic/mixed bipolar I patients for up to 6 months (after ≥ 8 
consecutive weeks of stability with open-label ziprasidone and lithium or valproate)82.  
 
 
8) LAMOTRIGINE PLUS MOOD STABILIZERS 
Acute treatment (≤ 8 weeks) 
Van der Loos and colleagues83 added lamotrigine or placebo to the ongoing lithium treatment of 
patients with bipolar depression.   
 
Longer term maintenance/relapse prevention (≥ 8 weeks) 
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Bowden and others trialled lamotrigine alone or in combination with divalproex-extended release in 
recently depressed patients with bipolar disorder in a maintenance study after 8-week open 
stabilization phase with lamotrigine or divalproex84.  
 
Discussion 
We found that the vast majority of published RCTs initially recruited both pure manic and mixed 
patients as defined in the DSM-IV classification system and that additional sub-analyses were 
performed to identify effects in a subgroup of mixed patients.  A major shortfall in the literature is 
that mixed depressive cases are not usually reported in depression RCTs. This subgroup approach 
has several shortcomings: first, the resulting sample sizes are usually small and thus “negative” 
trials could have been underpowered to detect existing differences between groups or “positive” 
trials might have an increased probability of being falsely positive; second, mixed patients enrolled 
in RCTs are probably less severely ill than those seen in clinical practice, and thirdly, the 
categorical definition of DSM-IV limits the number of patients thus identified, since it requires the 
co-occurrence of a full manic and a full depressive episode. Additional limitations of our work must 
be acknowledged.  Although our search strategy was comprehensive and included several search 
terms, there is still the chance that we have missed relevant papers or studies. This review did not 
include books, or clinical trials that have looked at the effects of other, non-pharmacological, 
treatment modalities such as psychosocial interventions or ECT. We report results distinguishing 
between manic and depressive outcomes when available, which may be more in line with the 
clinical need to know to what extent the chosen medication is able to resolve both manic and 
depressive symptoms in mixed states and bipolar depression or, conversely, to independently treat 
one or the other. Moreover, this is in line with the new “with mixed features” categorization of 
mood episodes in DSM-5, as the distinction in efficacy based on the polarity of concomitant 
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symptoms may be closer to the real clinical setting. The currently available evidence does not meet 
meet clinicians’ demands. Therefore, there is a clear need to conduct well-powered trials 
specifically designed to enrol the full range of mixed features. 
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